You are here

Application for Fabry Disease Treatment Pulled From FDA Review

The drug, Replagal, is an enzyme replacement therapy for the disease, which causes fat to build up in the body.

Shire had filed in November for FDA approval for Replagal, "in anticipation of a quick review process," the company said.

Shire has been permitted to supply the drug to the U.S. market after manufacturing problems in 2009 led to short supplies of rival drug Fabrazyme, which is made by Genzyme, now owned by Sanofi SA. Replagal has been on the market in Europe since 2001.

The FDA said Shire has also decided to end that treatment program over the next few months, and the drug will no longer be available to U.S. patients.

Read the full article on Reuters

Recent Headlines

Up to 70% Greater Risk of Bacterial Infection, 48% Risk for Fungal Infection
Patients Had Improved Lung Function, Fewer Exacerbations
Particularly Serious: Antidepressants, Drugs for Parkinson’s and Epilepsy
Drug “Remarkably Effective” at Killing Range of Gram-Positive Bacteria
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile